Skip to main content

Advertisement

Table 1 Characteristics of pulmonary TB cases stratified according to glycemic status

From: High prevalence and heterogeneity of Dysglycemia in patients with tuberculosis from Peru: a prospective cohort study

Characteristics n/N TBDM TBpreDM Normoglycemic p-value
n = 19 n = 42 n = 75
Age (years)-median (IQR) 136/136 46.41 (33.5–54.8) 39.8 (26.7–54.0) 26.4 (22.3–34.7) < 0.01
Gender 136/136     0.354
 Male 136/136 9 (47.4) 27 (64.3) 47 (62.7)  
 Female 136/136 10 (52.6) 15 (35.7) 28 (37.3)  
Prior TB 136/136 5 (26.3) 8 (19.0) 10 (13.3) 0.158
BCG vaccination 135/136 17 (89.5) 38 (92.7) 71 (94.7) 0.411
Smoking 135/136 4 (21.1) 10 (24.4) 15 (20.0) 0.767
Smokers at home 135/136 2 (10.5) 4 (9.8) 5 (6.7) 0.499
Cannabis use 135/136 1 (5.3) 7 (17.1) 13 (17.3) 0.283
Illicit drug use 135/136 2 (10.5) 7 (17.1) 8 (10.7) 0.707
Alcohol use 135/136 4 (21.1) 29 (70.7) 37 (49.3) 0.348
Hypertension 135/136 4 (21.1) 3 (7.3) 0 (0.0) < 0.01
Asthma 135/136 0 (0.0) 3 (7.3) 5 (6.7) 0.399
Renal disease 135/136 1 (5.3) 0 (0.0) 2 (2.7) 0.844
Slow scarring 135/136 3 (15.8) 9 (22.0) 7 (9.3) 0.186
Metformin use 132/136 7 (36.8) 0 (0.0) 0 (0.0) < 0.01
BMI (kg/m2)-median (IQR) 132/136 22.3 (21.4–26.4) 23.2 (21.2–25.1) 22.3 (20.3–25.4) 0.749
Waist circumference (cm) -median (IQR) 132/136 85 (81–89) 88 (80–91) 83 (76–88) 0.058
Hb (g/dL) -median (IQR) 134/136 9.9 (7.6–13.4) 12.0 (10.8–13.1) 12.6 (11.3–13.4)  
Anemia 136/136 19 (100) 31 (73.8) 49 (66.2) 0.006
FPG (mg /dL) -median (IQR) 136/136 218.9 (147.7–298.1) 103.1 (100.4–106.3) 89.7 (85.6–93.9) < 0.01
HbA1c (%)-median (IQR) 134/136 10.8 (7.4–13.5) 5.1 (4.8–5.5) 5.00 (4.6–5.1) < 0.01
OGTT (mg/dL) -median (IQR) 112/136 119.5 (119.5–119.5) 128.5 (106.5–157.1) 105.2 (85.8–121.4) < 0.01
AFB smear 135/136     0.004
 Negative   5 (26.3) 15 (35.7) 40 (54.1)  
 1+   3 (15.8) 9 (21.4) 15 (20.3)  
 2+   3 (15.8) 6 (14.3) 6 (8.1)  
 3+   7 (36.8) 10 (23.8) 11 (14.9)  
 Scanty   1 (5.3) 2 (4.8) 2 (2.7)  
L-J culture 131/136     0.59
 Negative   4 (21.1) 9 (22.5) 25 (34.2)  
 1+   12 (63.2) 18 (45.0) 33 (45.2)  
 2+   2 (10.5) 4 (10.0) 3 (4.2)  
 3+   0 (0.0) 4 (10.0) 3 (4.2)  
 colonies   1 (5.3) 5 (12.5) 8 (11.1)  
BD MGIT™ 960 System 78/136     0.11
 Positive   8 (80.0) 22 (81.5) 34 (82.9)  
 Negative   2 (20.7) 5 (18.5) 7 (17.1)  
MDR 76/136 2 (18.2) 3 (12.5) 4 (9.8) 0.451
Isoniazid-resistant 76/136 2 (18.2) 5 (20.8) 7 (17.1) 0.831
Rifampicin-resistant 76/136 2 (18.2) 4 (16.7) 5 (12.2) 0.55
TB treatment outcome 115/136     0.64
 Poor   5 (27.8) 8 (23.5) 14 (22.2)  
 Cure   13 (72.2) 26 (76.5) 49 (77.8)  
Polyuria 136/136 9 (47.4) 16 (38.1) 28 (37.3) 0.493
Polydipsia 136/136 9 (47.4) 20 (47.6) 36 (48.0) 0.956
  1. Data represent no. (%); IQR: Interquartile range. BCG Bacillus Calmette–Guérin, BMI Body Mass Index, Hb Hemoglobin, FPG Fasting Plasma Glucose, HbA1c Glycated Hemoglobin, OGTT Oral Glucose Tolerance Test, AFB Acid-Fast Bacilli, L-J Löwenstein-Jensen, MDR Multi Drug Resistant. Hypertension, asthma, renal disease and anemia as defined by the World Health Organization as described in Methods. Prior TB: diagnosis of active tuberculosis before of this